Pellepharm, Inc.

ACTIVE

10 S La Salle St Ste 3300, 加利福尼亚州圣马特奥县, California, United Stateswww.pellepharm.comHolding11–50 employeesEstablished: 2012-01-01

Clinical Trials

14 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2012

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

77.8%

Phase 2

11.1%

Phase 3

11.1%

Trial Status Distribution

Active, not recruiting

77.8%

Completed

22.2%

Clinical Trials

Trials sponsored by this organization (18)

Study of Topical Application of a Gel Containing the Investigational Active Ingredient Patidegib versus the same Gel Without Patidegib (Placebo) for the Prevention of New Facial Skin Tumors (Basal Cell Carcinomas) in People with Gorlin Syndrome.

Phase 1

Active, not recruiting

Jan 2021150 participants

A Phase 3, Multicenter, unblinded Extension Study of Patidegib Topical Gel, 2% in patient with Gorlin Syndrome

Phase 1

Active, not recruiting

May 2020200 participants

A Phase 3, Multicenter, unblinded Extension Study of Patidegib Topical Gel, 2% in patient with Gorlin Syndrome

Phase 1

Active, not recruiting

Apr 2020200 participants

A Phase 3, Multicenter, unblinded Extension Study of Patidegib Topical Gel, 2% in patient with Gorlin Syndrome

Phase 1

Active, not recruiting

Apr 2020200 participants

A Phase 3, Multicenter, unblinded Extension Study of Patidegib Topical Gel, 2% in patient with Gorlin Syndrome

Phase 1

Active, not recruiting

Mar 2020200 participants

A Phase 3, Multicenter, unblinded Extension Study of Patidegib Topical Gel, 2% in patient with Gorlin Syndrome

Phase 1

Active, not recruiting

Mar 2020200 participants

A 1-year Study of Topical Application of a Gel Containing the Investigational Active Ingredient Patidegib versus the same Gel Without Patidegib (Placebo) for the Prevention of New Facial Skin Tumors (Basal Cell Carcinomas) in People with Gorlin Syndrome

Phase 1

Active, not recruiting

Jun 2019150 participants

A 1-year Study of Topical Application of a Gel Containing the Investigational Active Ingredient Patidegib versus the same Gel Without Patidegib (Placebo) for the Prevention of New Facial Skin Tumors (Basal Cell Carcinomas) in People with Gorlin Syndrome

Phase 1

Active, not recruiting

Feb 2019150 participants

Page 1 of 3

Approvals

No approval data available

News

No news articles found

Back to Organizations